Specialty Chemical Stock Expands Manufacturing Capacity With Rs 255 Mn API Facility Investment

Sudarshan Pharma Industries reaches a definitive agreement with Srigen Lifesciences and increases manufacturing capacity through a strategic investment in an operational API facility. A major strategic capital expenditure investment was announced by the company on Monday as a result of a final agreement with Srigen Lifesciences Private Limited (Srigen), an API manufacturing company, for the transfer of capital assets, including land, buildings, and plant and machinery, at a fully functional manufacturing facility situated in Telangana at a cost of Rs. 25.50 Cr.

The Rs 255 million investment demonstrates SPIL's dedication to product diversity, operational effectiveness, and vertical integration. High-value, technically complex pharmaceutical ingredients such as Ropivacaine, Bupivacaine, Probenecid (Probalan), Sitagliptin, Apixaban, and Rivaroxaban-essential APIs and intermediates with high demand across regulated and semi-regulated markets-will be produced at the acquired facility.

"This high-impact move will result into massive growth in SPIL's manufacturing capacity and will substantially accelerate its trajectory in the high-growth Active Pharmaceutical Ingredients (API) and specialty chemicals sectors, resulting into incremental footprint in the domestic and global market. The transaction forms a cornerstone of SPIL's long-term strategy to build a robust, scalable, and compliance-driven manufacturing infrastructure to support global expansion and drive sustained value creation for stakeholders," said Sudarshan Pharma Industries in a regulatory statement.

Sachin Mehta, Joint Managing Director & Chief Financial Officer, SPIL, commented: "This investment represents a pivotal milestone in Sudarshan Pharma's growth agenda. It not only strengthens our manufacturing backbone but also significantly enhances our ability to serve global markets with agility, quality, and regulatory compliance. This addition is expected to contribute meaningfully to both revenue and profitability, supporting stronger financial performance and long-term shareholder value creation."

Sudarshan Pharma Industries further informed to stock exchanges that the strategic rationale and benefits of the above strategic capex investment are that the facility adds instant production capacity, accelerating supply chain responsiveness and overall throughput, can significantly reduce product launch timelines compared to greenfield projects, the facility is capable of producing complex, high-margin molecules, further enhancing SPIL's offerings in global therapeutic markets and the facility's proven compliance track record and comprehensive regulatory documentation are expected to shorten approval cycles and lower regulatory costs.

Meanwhile, an update about its application for the Production Linked Incentive (PLI) Scheme was released by Sudarshan Pharma Industries Limited (SPIL). The Ministry of Chemicals and Fertilizers' Department of Pharmaceuticals gave the company permission on Monday to relocate its greenfield projects from MIDC, Maharashtra, to GIDC, Gujarat.

Additionally, the authorization extends the planned date of commercial operation for vitamin B1 and vitamin B6 production to December 31, 2027. Prior to this, the corporation had been given an extension until March 31, 2025, for the commercial operation date of both projects; nevertheless, local resistance prevented them from being put into service.

Financially speaking, Sudarshan Pharma Industries' net profit plummeted 28.91% to Rs 4.18 crore in the September 2025 quarter compared to Rs 5.88 crore in the September 2024 quarter. Compared to Q2FY25, when sales were Rs 128.58 crore, Q2FY26 saw a 31.33% growth to Rs 168.87 crore.